Comparison · NCT00692770-sae
Sorafenib (Nexavar, BAY43-9006) vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sorafenib (Nexavar, BAY43-9006) vs Placebo: serious adverse events. Trial comparisons, record NCT00692770-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00692770-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.408 | 0.368 | 0.449 | wilson | |
| Risk in group 2 | 0.42 | 0.379 | 0.461 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0118 | -0.0696 | 0.046 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.972 | 0.845 | 1.12 | log | |
| Odds ratio, group 1 over group 2 | 0.952 | 0.75 | 1.21 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Sorafenib (Nexavar, BAY43-9006) than on Placebo | 84.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sorafenib (Nexavar, BAY43-9006) | Subjects received 2 tablets of Sorafenib \[2\*200 milligram (mg)\] orally twice daily. | 228 | 559 | EG001 |
| Group 2 | Placebo | Subjects received 2 tablets of placebo orally twice daily. | 230 | 548 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the date of signing informed consent up to 30 days post-treatment discontinuation
Source ClinicalTrials.gov
Trial
- Title
- Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
- NCT number
- NCT00692770
- Phases
- PHASE3
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Nexavar (Sorafenib, BAY43-9006), Placebo
- Lead sponsor
- Bayer
- Results first posted
- 2014-12-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00692770?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00692770-sae